mad money Lightning Round

On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes NextEra Energy, Inc. (NYSE:NEE) and recommended buying the same. “I think you've got a good one,” he added. On Jan. 24, NextEra Energy Inc posted in-line earnings for the fourth quarter and said it continues to...

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended not buying Bitdeer Technologies Group (NASDAQ:BTDR) and going with Bitcoin (CRYPTO: BTC). As per the recent news, Bitdeer announced the successful close of the acquisition of a fully licensed and permitted 101 MW site and gas...

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying AbbVie Inc. (NYSE:ABBV), saying it's “just a gem” and a “winner.”  He added, “I can't believe the stock dropped so much.” On Jan. 31, AbbVie reported fourth-quarter adjusted...

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Five9, Inc. (NASDAQ:FIVN), saying the stock is “way too cheap.” On the earnings front, Five9 will hold for its fourth quarter and fiscal year 2024 financial results conference call on Thursday, Feb. 20....

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Summit Therapeutics Inc. (NASDAQ:SMMT) has no revenues. He added, “It's obviously just a very big spec. I can't go there.” However, HC Wainwright & Co. analyst Mitchell Kapoor, on Jan. 21, reiterated Summit...

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Plains All American Pipeline, L.P. (NASDAQ:PAA) is a buy. Adding support to this choice, Raymond James analyst Justin Jenkins, on Tuesday, maintained Plains All American with a Strong Buy rating and raised the price target from $23...

On CNBC's “Mad Money Lightning Round,” Jim Cramer said he likes Keysight Technologies, Inc. (NYSE:KEYS) and recommended buying the same. “Terrific business, niche business,” he added. Supporting his view, JPMorgan analyst Samik Chatterjee, on Dec. 16, upgraded Keysight from...

On CNBC's “Mad Money Lightning Round,” Jim Cramer said First Solar, Inc. (NASDAQ:FSLR) is a “very inexpensive” stock. First Solar, meanwhile, will report financial results for the fourth quarter and full year ended Dec. 31, 2024, after the closing bell on Tuesday, Feb. 25,...

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying BlackRock, Inc. (NYSE:BLK) and added, “The long-term growth rate of this thing is fabulous, and I think it's going to stay that way.” BlackRock, on Jan. 15, reported better-than-expected fourth-quarter...

On CNBC's “Mad Money Lightning Round,” Jim Cramer said he is worried about The Wendy’s Company (NASDAQ:WEN). Cramer says it should not have a 7% yield, adding, “That, to me, suggests something may be wrong here. Morgan Stanley analyst John Glass supported his view on Jan. 21...

This Is A Meme Stock On CNBC's “Mad Money Lightning Round,” Jim Cramer said SoundHound AI (NASDAQ:SOUN) is a meme stock. “I'm never going to get in the way of a meme stock because you never know how high they can go,” he added. Shares of SoundHound AI rose sharply on Tuesday...

Thumbs Up For This Stock On CNBC's “Mad Money Lightning Round,” Jim Cramer said Sportradar Group AG (NASDAQ:SRAD) is speculative but he likes it. “I think you're into something good,” he added. Supporting his view, Jefferies analyst David Katz, on Jan. 15, maintained...

Tech Stocks In Focus On CNBC's “Mad Money Lightning Round,” Jim Cramer said Rigetti Computing, Inc. (NASDAQ:RGTI) is a quantum stock. “If you want to participate in a short squeeze, this is better than most,” he added. Shares of quantum stocks, including Rigetti Computing,...

Stocks To Buy: Cramer On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Robinhood (NASDAQ:HOOD). On Jan. 13, the U.S. Securities and Exchange Commission (SEC) announced that Robinhood Securities LLC and Robinhood Financial LLC will pay a combined $45 million in civil...

Pfizer Inc (NYSE:PFE) shares are just "too low to sell," according to Jim Cramer, host of CNBC’s "Mad Money Lightning Round." Hold the stock and let "the dividend do the job," Cramer advises, preferring to wait for "some good news" on the Seagen acquisition. Pfizer stock is down more than 7...